Skip to main content
Top
Published in: BMC Public Health 1/2024

Open Access 01-12-2024 | Research

Living with trimethylaminuria and body and breath malodour: personal perspectives

Authors: Cole C. Flaherty, Ian R. Phillips, Azara Janmohamed, Elizabeth A. Shephard

Published in: BMC Public Health | Issue 1/2024

Login to get access

Abstract

Background

Many people suffer from body and breath malodour syndromes. One of these is trimethylaminuria, a condition characterized by excretion in breath and bodily fluids of trimethylamine, a volatile and odorous chemical that has the smell of rotting fish. Trimethylaminuria can be primary, due to mutations in the gene encoding flavin-containing monooxygenase 3, or secondary, due to various causes. To gain a better understanding of problems faced by United Kingdom residents affected by body and breath malodour conditions, we conducted a survey.

Methods

Two anonymous online surveys, one for adults and one for parents/guardians of affected children, were conducted using the Opinio platform. Participants were invited via a trimethylaminuria advisory website. Questions were a mix of dropdown, checkbox and open-ended responses. Forty-four adults and three parents/guardians participated. The dropdown and checkbox responses were analysed using the Opinio platform.

Results

All participants reported symptoms of body/breath odour. However, not all answered every question. Twenty-three respondents experienced difficulties in being offered a diagnostic test for trimethylaminuria. Problems encountered included lack of awareness of the disorder by medical professionals and reluctance to recognise symptoms. Of those tested, 52% were diagnosed with trimethylaminuria. The main problems associated with living with body/breath malodours were bullying, harassment and ostracism in either the workplace (90%) or in social settings (88%). All respondents thought their condition had disadvantaged them in their daily lives. Open-ended responses included loss of confidence, stress, exclusion, isolation, loneliness, depression and suicidal thoughts. Respondents thought their lives could be improved by greater awareness and understanding of malodour conditions by medical professionals, employers and the general public, and appreciation that the malodour was due to a medical condition and not their fault.

Conclusions

Breath and body malodour conditions can cause immense hardship and distress, both mentally and socially, having devastating effects on quality of life. It would be advantageous to establish a standardised pathway from primary care to a specialist unit with access to a robust and reliable test and diagnostic criteria. There is a need to recognise malodour disorders as a disability, giving affected individuals the same rights as those with currently recognised disabilities.
Literature
1.
go back to reference Mitchell SC, Smith RL, Trimethylaminuria. The fish malodor syndrome. Drug Metab Dispos. 2001;29:517–21.PubMed Mitchell SC, Smith RL, Trimethylaminuria. The fish malodor syndrome. Drug Metab Dispos. 2001;29:517–21.PubMed
2.
3.
go back to reference Zhang AQ, Mitchell SC, Smith RL. Exacerbation of symptoms of fish-odour syndrome during menstruation. Lancet. 1996;348:1740–1.CrossRefPubMed Zhang AQ, Mitchell SC, Smith RL. Exacerbation of symptoms of fish-odour syndrome during menstruation. Lancet. 1996;348:1740–1.CrossRefPubMed
4.
go back to reference Fennema D, Phillips IR, Shephard EA. Trimethylamine and trimethylamine N-oxide, a flavin-containing monooxygenase 3 (FMO3)-mediated host-microbiome metabolic axis implicated in health and disease. Drug Metab Dispos. 2016;44:1839–50.CrossRefPubMedPubMedCentral Fennema D, Phillips IR, Shephard EA. Trimethylamine and trimethylamine N-oxide, a flavin-containing monooxygenase 3 (FMO3)-mediated host-microbiome metabolic axis implicated in health and disease. Drug Metab Dispos. 2016;44:1839–50.CrossRefPubMedPubMedCentral
5.
go back to reference Mitchell SC, Zhang AQ, Smith RL. Chemical and biological liberation of trimethylamine from foods. J Food Compos Anal. 2002;15:277–82.CrossRef Mitchell SC, Zhang AQ, Smith RL. Chemical and biological liberation of trimethylamine from foods. J Food Compos Anal. 2002;15:277–82.CrossRef
6.
go back to reference Mackay RJ, McEntyre CJ, Henderson C, Lever M, George PM. Trimethylaminuria: causes and diagnosis of a socially distressing condition. Clin Biochem. 2011;32:33–43. Mackay RJ, McEntyre CJ, Henderson C, Lever M, George PM. Trimethylaminuria: causes and diagnosis of a socially distressing condition. Clin Biochem. 2011;32:33–43.
8.
go back to reference Dolphin CT, Janmohamed A, Smith RL, Shephard EA, Phillips IR. Compound heterozygosity for missense mutations in the flavin-containing monooxygenase 3 (FM03) gene in patients with fish-odour syndrome. Pharmacogenetics. 2000;10:799–807.CrossRefPubMed Dolphin CT, Janmohamed A, Smith RL, Shephard EA, Phillips IR. Compound heterozygosity for missense mutations in the flavin-containing monooxygenase 3 (FM03) gene in patients with fish-odour syndrome. Pharmacogenetics. 2000;10:799–807.CrossRefPubMed
9.
go back to reference Dolphin CT, Janmohamed A, Smith RL, Shephard EA, Phillips IR. Missense mutation in flavin-containing mono-oxygenase 3 gene, FMO3, underlies fish-odour syndrome. Nat Genet. 1997;17:491–4.CrossRefPubMed Dolphin CT, Janmohamed A, Smith RL, Shephard EA, Phillips IR. Missense mutation in flavin-containing mono-oxygenase 3 gene, FMO3, underlies fish-odour syndrome. Nat Genet. 1997;17:491–4.CrossRefPubMed
10.
go back to reference Treacy EP, Akerman BR, Chow LML, Youil R, Bibeau C, Lin J, et al. Mutations of the flavin-containing monooxygenase gene (FMO3) cause trimethylaminuria, a defect in detoxication. Hum Mol Genet. 1998;7:839–45.CrossRefPubMed Treacy EP, Akerman BR, Chow LML, Youil R, Bibeau C, Lin J, et al. Mutations of the flavin-containing monooxygenase gene (FMO3) cause trimethylaminuria, a defect in detoxication. Hum Mol Genet. 1998;7:839–45.CrossRefPubMed
11.
go back to reference Lang D, Yeung C, Peter R, Ibarra C, Gasser R, Itagaki K, et al. Isoform specificity of trimethylamine N-oxygenation by human flavin-containing monooxygenase (FMO) and P450 enzymes. Biochem Pharmacol. 1998;56:1005–12.CrossRefPubMed Lang D, Yeung C, Peter R, Ibarra C, Gasser R, Itagaki K, et al. Isoform specificity of trimethylamine N-oxygenation by human flavin-containing monooxygenase (FMO) and P450 enzymes. Biochem Pharmacol. 1998;56:1005–12.CrossRefPubMed
12.
go back to reference Phillips IR, Shephard EA. Flavin-containing monooxygenases: mutations, disease and drug response. TIPS. 2008;29:294–301.PubMed Phillips IR, Shephard EA. Flavin-containing monooxygenases: mutations, disease and drug response. TIPS. 2008;29:294–301.PubMed
13.
go back to reference Philips IR, Francois AA, Shephard EA. The flavin-containing monooxygenases (FMOs): genetic variation and its consequences for the metabolism of therapeutic drugs. Curr Pharmacogenomics. 2007;5:292–313.CrossRef Philips IR, Francois AA, Shephard EA. The flavin-containing monooxygenases (FMOs): genetic variation and its consequences for the metabolism of therapeutic drugs. Curr Pharmacogenomics. 2007;5:292–313.CrossRef
14.
go back to reference Yamazaki H, Shimizu M. Survey of variants of human flavin-containing monooxygenase 3 (FMO3) and their drug oxidation activities. Biochem Pharmacol. 2013;85:1588–93.CrossRefPubMed Yamazaki H, Shimizu M. Survey of variants of human flavin-containing monooxygenase 3 (FMO3) and their drug oxidation activities. Biochem Pharmacol. 2013;85:1588–93.CrossRefPubMed
15.
go back to reference Shimizu M, Allerston CK, Shephard EA, Yamazaki H, Phillips IR. Relationships between flavin-containing mono-oxygenase 3 (FMO3) genotype and trimethylaminuria phenotype in a Japanese population. Br J Clin Pharmacol. 2014;77:839–51.CrossRefPubMedPubMedCentral Shimizu M, Allerston CK, Shephard EA, Yamazaki H, Phillips IR. Relationships between flavin-containing mono-oxygenase 3 (FMO3) genotype and trimethylaminuria phenotype in a Japanese population. Br J Clin Pharmacol. 2014;77:839–51.CrossRefPubMedPubMedCentral
16.
go back to reference Zhang AQ, Mitchell SC, Smith RL. Discontinuous distribution of N-oxidation of dietary-derived trimethylamine in a British population. Xenobiotica. 1996;26:957–61.CrossRefPubMed Zhang AQ, Mitchell SC, Smith RL. Discontinuous distribution of N-oxidation of dietary-derived trimethylamine in a British population. Xenobiotica. 1996;26:957–61.CrossRefPubMed
18.
go back to reference Cashman JR, Camp K, Fakharzadeh SS, Fennessey PV, Hines RN, Mamer OA, et al. Biochemical and clinical aspects of the human flavin-containing monooxygenase form 3 (FMO3) related to trimethylaminuria. Curr Drug Metab. 2003;4:151–70.CrossRefPubMed Cashman JR, Camp K, Fakharzadeh SS, Fennessey PV, Hines RN, Mamer OA, et al. Biochemical and clinical aspects of the human flavin-containing monooxygenase form 3 (FMO3) related to trimethylaminuria. Curr Drug Metab. 2003;4:151–70.CrossRefPubMed
19.
go back to reference Roddy D, McCarthy P, Nerney D, Mulligan-Rabbitt J, Smith E, Treacy EP. Impact of trimethylaminuria on daily psychosocial functioning. JIMD Rep. 2021;57:67–75.CrossRefPubMed Roddy D, McCarthy P, Nerney D, Mulligan-Rabbitt J, Smith E, Treacy EP. Impact of trimethylaminuria on daily psychosocial functioning. JIMD Rep. 2021;57:67–75.CrossRefPubMed
20.
go back to reference Lateef A, Marshall-Lucette S. Living with Trimethylaminuria (TMAU) from an adult viewpoint. Pract Nurs. 2017;28:344–51.CrossRef Lateef A, Marshall-Lucette S. Living with Trimethylaminuria (TMAU) from an adult viewpoint. Pract Nurs. 2017;28:344–51.CrossRef
21.
go back to reference Rutkowski K, Rahman Y, Halter M. Development and feasibility of the use of an assessment tool measuring treatment efficacy in patients with trimethylaminuria: a mixed methods study. J Inherit Metab Dis. 2019;42:362–70.CrossRefPubMed Rutkowski K, Rahman Y, Halter M. Development and feasibility of the use of an assessment tool measuring treatment efficacy in patients with trimethylaminuria: a mixed methods study. J Inherit Metab Dis. 2019;42:362–70.CrossRefPubMed
22.
go back to reference Amoore JE, Forrester LJ. Specific anosmia to trimethylamine: the fishy primary odor. J Chem Ecol. 1976;2:49–56.CrossRef Amoore JE, Forrester LJ. Specific anosmia to trimethylamine: the fishy primary odor. J Chem Ecol. 1976;2:49–56.CrossRef
24.
27.
go back to reference Busby MG, Fischer L, Da Costa K-A, Thompson D, Mar M-H, Zeisel SH. Choline- and betaine-defined diets for use in clinical research and for the management of trimethylaminuria. J Am Diet Assoc. 2004;104:1836–45.CrossRefPubMed Busby MG, Fischer L, Da Costa K-A, Thompson D, Mar M-H, Zeisel SH. Choline- and betaine-defined diets for use in clinical research and for the management of trimethylaminuria. J Am Diet Assoc. 2004;104:1836–45.CrossRefPubMed
28.
go back to reference Schmidt AC, Leroux J-C. Treatments of trimethylaminuria: where we are and where we might be heading. Drug Discov Today. 2020;25:1710–7.CrossRefPubMed Schmidt AC, Leroux J-C. Treatments of trimethylaminuria: where we are and where we might be heading. Drug Discov Today. 2020;25:1710–7.CrossRefPubMed
29.
go back to reference Phillips IR, Shephard EA. Drug metabolism by flavin-containing monooxygenases of human and mouse. Expert Opin Drug Metab Toxicol. 2017;13:167–81.CrossRefPubMed Phillips IR, Shephard EA. Drug metabolism by flavin-containing monooxygenases of human and mouse. Expert Opin Drug Metab Toxicol. 2017;13:167–81.CrossRefPubMed
Metadata
Title
Living with trimethylaminuria and body and breath malodour: personal perspectives
Authors
Cole C. Flaherty
Ian R. Phillips
Azara Janmohamed
Elizabeth A. Shephard
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2024
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-024-17685-w

Other articles of this Issue 1/2024

BMC Public Health 1/2024 Go to the issue